Hematologist-oncologist and author Vinay Prasad, MD, MPH, dismantles claims that ivermectin and fenbendazole are miracle cancer cures, while also criticizing the FDA’s approval process for expensive anti-cancer drugs…
Jimmy Ruiz, MD, reflects on his career journey in North Carolina and the transformative progress in lung cancer treatment. Early in his career, limited tools like chemotherapy presented…
NEW YORK (Reuters Health) – Statin therapy is associated with a reduced risk of hepatocellular carcinoma in patients with diabetes, according to a report in the June issue…
NEW YORK (Reuters Health) – Treatment of prostate cancer with androgen deprivation therapy is associated with an excess risk of incident diabetes and fractures, but not MI or…
Joe Minniti, the Executive Director of the Cancer Foundation for Personal Appearance and Larry Cohen, Executive Vice President of the NIA Group, talk about the NIA group’s support…
Michael Banks, MD, provides an overview of diffuse brainstem gliomas. This video is dedicated to the memory of Max Scotti. About Making Headway Foundation Making Headway® is a…
NEW YORK (Reuters Health) – Initiating second-line chemotherapy for ovarian cancer recurrence based on an increase in the tumor marker CA125 alone does not improve overall survival compared…
NEW YORK (Reuters Health) – Most patients with synchronous metastatic (stage IV) colorectal cancer can forgo surgery to remove the primary tumor, at least initially, opting instead for…
NEW YORK (Reuters Health) – Rituximab (Rituxan) has been implicated in 57 cases of progressive multifocal leukoencephalopathy (PML) in HIV-negative patients diagnosed with hematologic malignancies or autoimmune diseases,…
NEW YORK (Reuters Health) – Combining hepatic artery infusion of floxuridine/dexamethasone with systemic oxaliplatin and irinotecan can make liver metastases from colorectal cancer resectable in about half of…
On April 22nd, 2009, people from around the globe gathered at US Cellular Field in Chicago to announce the Learning Living & Loving campaign. This call to action…
NEW YORK (Reuters Health) – Advanced prostate cancer appears to be of a more aggressive type when it occurs in young men, leading to dramatically higher cancer-specific mortality…
